Freeline Therapeutics Holdings Alpha and Beta Analysis
| FRLNDelisted Stock | USD 4.31 0.28 6.10% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Freeline Therapeutics Holdings. It also helps investors analyze the systematic and unsystematic risks associated with investing in Freeline Therapeutics over a specified time horizon. Remember, high Freeline Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Freeline Therapeutics' market risk premium analysis include:
Beta 1.09 | Alpha (0.12) | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Freeline |
Freeline Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Freeline Therapeutics market risk premium is the additional return an investor will receive from holding Freeline Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Freeline Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Freeline Therapeutics' performance over market.| α | -0.12 | β | 1.09 |
Freeline Therapeutics Fundamentals Vs Peers
Comparing Freeline Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Freeline Therapeutics' direct or indirect competition across all of the common fundamentals between Freeline Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Freeline Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Freeline Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Freeline Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Freeline Therapeutics to competition |
| Fundamentals | Freeline Therapeutics | Peer Average |
| Return On Equity | -1.01 | -0.31 |
| Return On Asset | -0.56 | -0.14 |
| Current Valuation | 2.78 M | 16.62 B |
| Shares Outstanding | 4.36 M | 571.82 M |
| Shares Owned By Insiders | 1.09 % | 10.09 % |
| Shares Owned By Institutions | 45.88 % | 39.21 % |
| Number Of Shares Shorted | 23.93 K | 4.71 M |
Freeline Therapeutics Opportunities
Freeline Therapeutics Return and Market Media
The Stock received some media coverage during the period. Price Growth (%) |
| Timeline |
1 | Both private equity firms who control a good portion of Freeline Therapeutics Holdings plc along with institutions must be dismayed after last weeks 11 percent ... | 05/12/2023 |
About Freeline Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Freeline or other delisted stocks. Alpha measures the amount that position in Freeline Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Freeline Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Freeline Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Freeline Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Freeline Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Freeline Therapeutics. Please utilize our Beneish M Score to check the likelihood of Freeline Therapeutics' management manipulating its earnings.
| 2nd of April 2024 Upcoming Quarterly Report | View | |
| 4th of June 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 2nd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Freeline Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in Freeline Stock
If you are still planning to invest in Freeline Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Freeline Therapeutics' history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |